Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Health Companies Inc BHC


Primary Symbol: T.BHC

Healthcare
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Recent & Breaking News (TSX:BHC)

PrCABTREOTM (clindamycin phosphate, adapalene and benzoyl peroxide gel) Treatment for Acne Vulgaris Receives Positive Reimbursement Recommendations from Canada's Drug Agency and Quebec's INESSS

Accesswire 8 days ago

Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

Accesswire 8 days ago

Bausch Health Announces Third Quarter 2024 Results

Accesswire October 30, 2024

ACG Presidential Plenary to Highlight Analysis of Xifaxan(R) (rifaximin) Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence

Accesswire October 27, 2024

Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

Accesswire October 9, 2024

Bausch Health and Salix Survey Highlights Urgent Need for Improved Understanding of Liver Disease Across Healthcare Provider Disciplines as Prevalence of Cirrhosis Rises

Accesswire October 8, 2024

Investor Alert and Limitation Period: Canadian investors that purchased shares of Bausch Health Companies, Inc. listed on the Toronto Stock Exchange need to act

Canada NewsWire September 30, 2024

Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

Accesswire September 11, 2024

Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners

Accesswire August 13, 2024

Bausch Health Announces Second Quarter 2024 Results

Accesswire July 31, 2024

Bausch Health Responds to Market Rumors

Accesswire July 24, 2024

Canadian Investment Regulatory Organization Trade Resumption - BHC

Canada NewsWire July 24, 2024

Canadian Investment Regulatory Organization Trading Halt - BHC

Canada NewsWire July 24, 2024

Bausch Health Welcomes Two New Members to the Executive Leadership Team

Accesswire July 19, 2024

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

Accesswire July 11, 2024

Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals

Accesswire June 20, 2024

Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences

Accesswire June 14, 2024

Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Accesswire May 23, 2024

Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Accesswire May 17, 2024

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

Accesswire May 15, 2024